fda glp-1 compounding warning october 2025 Today, the is announcing its intent to take decisive steps to restrict active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including The Refill, Issue 13: FDA

22,4042 The efficacy of GLP-1 RAs in depressive symptoms primarily derives from animal studies, making it challenging to draw definitive conclusions

patients overcame many barriers by paying cash 53% of filled GLP-1 scripts were cash-paid in 2024 (up from 11% in 2023) ( [11] )

Participants treated with liraglutide (239), semaglutide (240), or tirzepatide (200) in the clinical trials had a percent reduction in fat mass approximately three times greater than the reduction in lean mass, leading to an overall improvement in body composition

People taking GLP-1 medications often notice improved energy and less fatigue when L-carnitine is included